Market news

BioVie (Nasdaq:BIVI) CEO Cuong Do Discusses the Company's Recent Long COVID Clinical Results and the Potential of Bezisterim to Address Significant Unmet Patient NeedsNEW YORK CITY, NY / ACCESS Newswire / September 19, 2026 / , one of the world's longest-running sponsored and syndicated business television programs, announces tonight's broadcast featuring executives from BioVie Inc. (Nasdaq:BIVI), Acurx Pharmaceuticals, Inc.

Detailed price information for Bayerische Motoren Werke ADR (BMWYY) from The Globe and Mail including charting and trades.

DALLAS, September 17, 2026--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, today announced that it will host a live webinar on Wednesday, September 23, 2026 at 12:30 PM Eastern to present the business model, development roadmap, and value proposition of Open-Medicine AI (OMAI), the company’s wholly owned subsidiary building a multi-agentic AI platform for end-to-end therapeu

October 3 Southeast Asia launch will add distribution reaching approximately 68 million householdsNEW YORK CITY, NY / ACCESS Newswire / September 5, 2026 / , the 18-year media brand serving public companies and companies aspiring to enter the public markets, today announced its latest broadcast airing at 6:30 PM ET across Bloomberg Television in the United States, Latin America and the Middle East and North Africa (MENA).The program features executive interviews and corporate updates from Lanter

Motley Fool Press Release.

Moby summary of Lantern Pharma Inc.'s Q2 2026 earnings call

DALLAS, August 14, 2026--Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

DALLAS, August 07, 2026--Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET

DALLAS, August 03, 2026--Open Medicine AI is launched as separate entity by Lantern Pharma.

DALLAS, July 28, 2026--EMA Phase 1b/2 Clinical Trial for LP-184

DALLAS, July 23, 2026--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence and genomic data to develop targeted cancer therapies, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 17/230,821, titled "Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers."

Lantern Pharma (LTRN) said Thursday that it has received approval from the US Patent and Trademark O

DALLAS, July 08, 2026--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced the launch of ZetaOmics, the computational-biology module of its multi-agentic AI co-scientist platform, withZeta.ai. ZetaOmics introduces an autonomous "Computational Biologist" persona (agent) that performs real, end-to-end bioinformatics and multi-omic analysis — across any cancer type, and is purpose-built for the rare and pediatric cancers that have long been un